MBA, CCO, Pillar Biosciences
Biography
Mr. Daniel J. Harma has more than 30 years of experience in the medical device industry, notably in in-vitro diagnostics, molecular diagnostics, and hematology markets. Prior to joining Pillar Biosciences, he served as Chief Commercial Officer at NeuMoDxTM where he led the commercial team and assisted in transitioning the business from research and development stage to full commercialization. Previously, he held multiple roles at Abbott Laboratories, Inc., in both the Diagnostics and Molecular divisions. His positions included oversight of product marketing, sales leadership, and commercial development. Mr. Harma received his MBA from Loyola University and his BBA in Marketing from the University of Wisconsin-Whitewater.
Talk
Clinical & Research Tools Showcase:
Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to quickly and accurately generate data that optimizes selection of precision therapies for cancer patients.
Leveraging NGS To Enable Localized Decision Medicine
Pillar Biosciences is enabling "Decision Medicine" by enabling localized, more accurate, cost effective and efficient NGS testing.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 2.45 P.M.-4.00 P.M.,Showcase Track S2 - January 26 1.30 P.M.-4.00 P.M.,Showcase Track S2 - January 27 1.15 P.M.-1.30 P.M.
The PMWC 2023 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
